Log in

ASX:BIT - Biotron Stock Price, Forecast & News

0.00 (0.00 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: A$0.08
50-Day Range
MA: A$0.11
52-Week Range
Now: A$0.08
Volume2.43 million shs
Average VolumeN/A
Market Capitalization$54.05 million
P/E RatioN/A
Dividend YieldN/A
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus. Biotron Limited is based in North Ryde, Australia.
Read More

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 9805 0488



Sales & Book Value

Annual SalesN/A
Cash FlowA$0.01 per share
Book ValueA$0.01 per share



Market Cap$54.05 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BIT News and Ratings via Email

Sign-up to receive the latest news and ratings for BIT and its competitors with MarketBeat's FREE daily newsletter.

Biotron (ASX:BIT) Frequently Asked Questions

How has Biotron's stock been impacted by COVID-19 (Coronavirus)?

Biotron's stock was trading at A$0.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BIT shares have decreased by 33.0% and is now trading at A$0.08. View which stocks have been mosted impacted by Coronavirus.

Has Biotron been receiving favorable news coverage?

Media stories about BIT stock have trended positive this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biotron earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutBiotron.

Who are some of Biotron's key competitors?

What other stocks do shareholders of Biotron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotron investors own include TPG Telecom (TPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), QUALCOMM (QCOM), Turquoise Hill Resources (TRQ), United Natural Foods (UNFI), Northern Star Resources (NST), Gemfields (GEM), Biosyent (RX) and Acasti Pharma (ACST).

Who are Biotron's key executives?

Biotron's management team includes the following people:
  • Dr. Michelle Miller BSc., GCertAppFin, Ph.D., MSc., CEO, MD & Exec. Director
  • Mr. Peter James Nightingale B.Econ, CA, Company Sec. (Age 62)

What is Biotron's stock symbol?

Biotron trades on the ASX under the ticker symbol "BIT."

What is Biotron's stock price today?

One share of BIT stock can currently be purchased for approximately A$0.08.

How big of a company is Biotron?

Biotron has a market capitalization of $54.05 million. Biotron employs 3 workers across the globe. View additional information about Biotron.

What is Biotron's official website?

The official website for Biotron is http://www.biotron.com.au/.

How can I contact Biotron?

The company can be reached via phone at 61 2 9805 0488.

MarketBeat Community Rating for Biotron (ASX BIT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  37
MarketBeat's community ratings are surveys of what our community members think about Biotron and other stocks. Vote "Outperform" if you believe BIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel